Tesaro shares skid low­er as As­traZeneca wows with PhI­II da­ta on PARP drug for ovar­i­an can­cer

As­traZeneca spelled out its im­pres­sive Phase III da­ta for Lyn­parza (ola­parib) pills, which will now line up against Tesaro’s ri­val PARP ni­ra­parib.

Pas­cal So­ri­ot

In a cen­tral, blind­ed re­view the drug achieved a me­di­an pro­gres­sion-free sur­vival rate of 30.2 months in germline BR­CA-mu­tat­ed, plat­inum-sen­si­tive, re­lapsed ovar­i­an can­cer pa­tients ver­sus 5.5 months for the place­bo arm. A sol­id suc­cess for As­traZeneca, which bad­ly needs to con­tin­ue to build up its on­col­o­gy group if CEO Pas­cal So­ri­ot ex­pects to achieve any­thing like the big turn­around he’s been promis­ing in­vestors for years.

The drug al­so achieved a sta­tis­ti­cal­ly sig­nif­i­cant re­sult in de­lay­ing the sec­ond pro­gres­sion or time to death, with the me­di­an rate not reached for Lyn­parza com­pared to 18.4 months for place­bo.

As­traZeneca got a jump on the PARP mar­ket with shaky ear­ly da­ta, which reined in its rev­enue po­ten­tial. The phar­ma gi­ant earned on­ly a bit more than $200 mil­lion on Lyn­parza last year, but ex­pects to in­crease that past the $1 bil­lion block­buster mark as it looks to broad­en its use as a main­te­nance ther­a­py in the US.

Tesaro $TSRO has been aim­ing at a di­rect show­down with As­traZeneca as it winds up for a like­ly near-term ap­proval on ni­ra­parib. Its re­duc­tion in risk com­pares close­ly to ola­parib, with a PFS rate that won’t look as good.

Tesaro’s ni­ra­parib da­ta high­light­ed a clear im­pact for the tar­get­ed drug in a pop­u­la­tion of germline BR­CA mu­ta­tion car­ri­ers, with a me­di­an PFS of 21 months in the drug group com­pared to 5.5 months in the con­trol arm — a 15.5-month ad­van­tage that will not com­pare well with Lyn­parza’s, which beat place­bo by slight­ly more than two years.

Sean Bo­hen

Tesaro’s shares skid­ded down 12.5% on the com­par­i­son. Clo­vis $CLVS, mean­while, which has had prob­lems of its own in de­vel­op­ing its new­ly ap­proved PARP Rubra­ca, saw its shares rise 6.9% as the horse race among all the PARPs looked tighter than ever.

Pfiz­er will look to join this group in the not too dis­tant fu­ture with its own piv­otal da­ta for a PARP — ta­la­zoparib — picked up in the $14 bil­lion Medi­va­tion ac­qui­si­tion.

“With these da­ta, we be­lieve it is very dif­fi­cult to chal­lenge the no­tion that the lead­ing PARPs (ni­ra­parib, ola­parib, ru­ca­parib, ta­la­zoparib) are more sim­i­lar than dif­fer­ent,” summed up Leerink’s Sea­mus Fer­nan­dez. “But fol­low­ing our con­ver­sa­tion with AZN, they are most fo­cused on the safe­ty and tol­er­a­bil­i­ty of ola­parib, which they be­lieve is a key area of dif­fer­en­ti­a­tion vs. ni­ra­parib.”

As­traZeneca R&D chief Sean Bo­hen said:

We are ex­treme­ly pleased with the re­sults from SO­LO-2, which sup­port the po­ten­tial ben­e­fit of LYN­PARZA tablets as a main­te­nance ther­a­py for pa­tients with re­lapsed ovar­i­an can­cer. The tablet for­mu­la­tion may of­fer pa­tients a re­duced pill bur­den for LYN­PARZA and a safe­ty pro­file that is gen­er­al­ly con­sis­tent with pre­vi­ous tri­als. We will work with reg­u­la­to­ry au­thor­i­ties to make LYN­PARZA tablets avail­able to pa­tients as quick­ly as pos­si­ble.

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Donald and Melania Trump watch the smoke of fireworks from the South Lawn of the White House on July 4, 2020 (via Getty)

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year.

— Donald Trump, July 4

Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn’t describe the study in any further detail because, they said, its disclosure would be “market-moving.”

— NBC News, July 3

Something’s cooking. And it’s not just July 4 leftovers involving stale buns and uneaten hot dogs.

Over the long weekend observers picked up signs that the focus in the Trump administration may swiftly shift from the bright spotlight on vaccines being promised this fall, around the time of the election, to include drugs that could possibly keep patients out of the hospital and take the political sting out of the soaring Covid-19 numbers causing embarrassment in states that swiftly reopened — as Trump cheered along.

So far, Gilead has been the chief beneficiary of the drive on drugs, swiftly offering enough early data to get remdesivir an emergency authorization and into the hands of the US government. But their drug, while helpful in cutting stays, is known for a limited, modest effect. And that won’t tamp down on the hurricane of criticism that’s been tearing at the White House, and buffeting the president’s most stalwart core defenders as the economy suffers.

We’ve had positive early-stage vaccine data, most recently from Pfizer and BioNTech, playing catchup on an mRNA race led by Moderna — where every little sign of potential trouble is magnified into a lethal threat, just as every advance excites a frenzy of support. But that race still has months to play out, with more Phase I data due ahead of the mid-stage numbers looming ahead. A vaccine may not be available in large enough quantities until well into 2021, which is still wildly ambitious.

So what about a drug solution?

Trump’s initial support for a panacea focused on hydroxychloroquine. But that fizzled in the face of data underscoring its ineffectiveness — killing trials that aren’t likely to be restarted because of a recent population-based study offering some support. And there are a number of existing drugs being repurposed to see how they help hospitalized patients.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II – re­ports; No­vavax se­cures largest Warp Speed deal yet: $1.6B

A much anticipated Phase III trial for Moderna’s Covid-19 vaccine is being held up as the company delayed submitting trial protocols and sparred with government scientists on how to run the study and even what the benchmark for success should be, Reuters reported.

Moderna, the first US company to put their vaccine into human testing, was supposed to enter a 30,000-person study this month in partnership with the NIH to determine whether it can prevent infection. STAT reported last week that the trial was facing delays over the protocol, but that a July start was still possible. Neither the NIH nor Moderna ever disclosed a specific date the trial should start, but Reuters reported that the agency had hoped to begin on July 10.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

In­vestors give ail­ing Unum a lease on life and a whole new suite of ex­per­i­men­tal can­cer drugs

Investors, it seems, are willing to give Unum Therapeutics one last shot — or at least one last shot to a company of that name.

The ailing cancer biotech, beset by a series of clinical holds and multiple failed lead programs, announced today that they’ve acquired Kiq LLC and that investors are putting in $104 million to advance Kiq’s pipeline of kinase inhibitors. Unum shareholders will now own only 16.2% of the company and CEO Chuck Wilson indicated that the cell therapies the biotech has worked on since its founding may be on their way out, saying Unum will “explore strategic options” for those products.

RA Cap­i­tal dou­bles down on Sid­dhartha Mukher­jee's vi­sion for a new cell en­gi­neer­ing ap­proach, lead­ing Vor's $110M Se­ries B

Vor Biopharma is muscling up.

CEO Robert Ang, who was reluctant to divulge the headcount when discussing his move from Neon Therapeutics to Vor last August, readily offered that the team has grown from 6 to 50 in less than a year. The biotech is moving to a larger office on Cambridge Parkway Drive in weeks, giving it more space to complete the IND-enabling work and manufacturing scale-up — conducted by a CDMO partner — in preparation for clinical trials planned for the first half of 2021.

Cel­lec­tis slammed af­ter pa­tient dies and FDA slaps a hold on their tri­al for an off-the-shelf CAR-T for mul­ti­ple myelo­ma

Cellectis was slammed after the market close on Monday as the biotech reported that the FDA demanded it hit the brakes on their MELANI-01 trial for their off-the-shelf cell therapy UCARTCS1A after one of the patients in the study died of treatment-related cardiac arrest.

The multiple myeloma patient had previously been treated unsuccessfully with various therapies, noted the biotech, and had been given dose level two (DL2) of their allogeneic CAR-T.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)

Sec­ond PhI­II study for Idor­si­a's sleep drug re­turns pos­i­tive re­sults, but al­so rais­es new ques­tions

Following a successful Phase III study in April showcasing the safety and potential of its new sleep drug, Idorsia posted some mixed news in the second Phase III study, but that won’t stop a planned filing aimed at regulatory approval.

The drug, a dual orexin receptor antagonist (DORA) called daridorexant, was found to significantly improve sleep maintenance and subjective total sleep time in 25 mg doses, replicating results from the first Phase III study. However, improvements in sleep onset and daytime functioning narrowly missed statistical significance, despite numerical consistency with the April study.

UP­DAT­ED: Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval

By the time the FDA finally granted an accelerated OK for Immunomedics’ Trodelvy, we already got a very strong hint that their confirmatory Phase III study in metastatic triple-negative breast cancer was a success.

That’s because the independent data safety monitoring committee recommended that the trial be stopped early. But just what pointed them to the conclusion was still unclear.

“We do not know the totality of their decision other than it’s pretty evident that the primary endpoint was met; otherwise they could not request to halt the study,” Behzad Aghazadeh, the executive chairman, told Endpoints News at the time.

Shoshanna Shendelman, Applied Therapeutics CEO (Applied Therapeutics)

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

As short attacks go, Biotech Research Partners’ assault on Applied Therapeutics’ “cherry picked” data and a variety of so-called red flags didn’t cause a whole lot of damage. Ahead of the July 4 holiday, its shares $APLT were dinged and showed signs of quick recovery.

But that didn’t stop an incendiary response, as the biotech swung into action bright and early Monday morning.

Applied Therapeutics accused the authors of the short report of manipulating graphs and figures, misrepresenting data and included factual misrepresentations — all of which added up, in their view, to fraud.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.